Rosaria Perone,Claudia Albertini,Elisa Uliassi,Flaminia Di Pietri,Pedro Sena Murteira Pinheiro,Sabrina Petralla,Nicola Rizzardi,Romana Fato,Lenka Pulkrabkova,Ondrej Soukup,Anna Tramarin,Manuela Bartolini,Maria Laura Bolognesi

Abstract:Thanks to the widespread use and safety profile of donepezil ( 1 ) in the treatment of Alzheimer0s disease (AD), one of the most widely adopted multi‐target‐directed ligand (MTDL) design strategies is to modify its molecular structure by linking a second fragment carrying an additional AD‐relevant biological property. Herein, supported by a proposed combination of 1 and quinone drug idebenone, we rationally designed novel 1 ‐based MTDLs targeting Aβ and oxidative pathways. By exploiting a bioisosteric replacement of the indanone core of 1 with a 1,4‐naphthoquinone, we ended up with a series of highly merged derivatives, in principle devoid of the "physicochemical challenge" typical of large hybrid‐based MTDLs. A preliminary investigation of their multi‐target profile identified 9 , which showed a potent and selective butyrylcholinesterase inhibitory activity, together with antioxidant and antiaggregating properties. In addition, it displayed a promising drug‐like profile.

Turning Donepezil into a Multi‐Target‐Directed Ligand through a Merging Strategy